Fig. 3

Intranasal IL-33 treatment protects against BBB damage in a microglia/macrophage-dependent manner. Mice were maintained on PLX5622 diet or control diet for 7 days and subjected to 60 min tMCAO. IL-33 or PBS was intranasally applied 2 h after ischemia and repeated daily for 3d. Brains were collected 3 days after stroke. (A) Representative coronal sections stained with antibodies against MAP2. (B) Quantification of infarct volumes on MAP2-stained sections. (C) Representative coronal sections immunolabeled for infiltrating IgGs. (D) Quantitative analysis of IgG intensity. (E) Representative images of CD31 (green) and Iba1 (white) immunostaining in the peri-infarct area. (F) Representative images of CD31 (red) and ZO-1 (green) double staining in the peri-infarct area. Cell nuclei are counterstained with DAPI (blue). (G) Quantification of the percentages of CD31⁺ vessels covered by ZO-1 staining. *P < 0.05, **P < 0.01. Two-way ANOVA followed by post hoc Bonferroni test